Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment II
2009-009858-24Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in primary myelofibrosis (PMF), myelofibrosis (MF) and post-polycythemia vera myelofibrosis (PPV-MF) (2 arms), sponsored by Novartis. Primary endpoint: Proportion of subjects achieving ≥35% reduction in spleen volume. Started Apr 2009; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on 2009-009858-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009858-24.